Pacific Biosciences upgraded to Neutral from Underweight at JPMorgan

theflyonthewall.com

JPMorgan upgraded Pacific Biosciences to Neutral citing valuation and stronger system placements following the company's Q1 results. The firm has a $7 price target for shares.

View Comments (0)